COLLCollegium Pharmaceutical, Inc.
$22.06-38% 1Y
$22.06
$21.8552 weeks$49.84
The financials
Collegium Pharmaceutical, Inc. by the numbers
Collegium Pharmaceutical, Inc. (COLL) reported revenue of $200M in Q2 2026 (quarter ended Jun 30, 2026), up 6.3% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $15M. For the full year FY2025, revenue was $781M (+24% year on year) and net income $63M. Its largest product in Q2 2026 was Belbuca at $58M, 29% of the disclosed total, just ahead of Jornay Pm at 23%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $200M | $188M | +6.3% |
| Gross profit | $110M | $108M | +1.8% |
| Operating income | $3.7M | $35M | −89% |
| Net income | −$15M | $12M | to a loss |
| Diluted EPS | −$0.46 | $0.34 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Belbuca | $58M | 29% |
| Jornay Pm | $46M | 23% |
| Xtampza ER | $45M | 23% |
| Nucynta ER | $16M | 7.9% |
| Nucynta IR | $14M | 7.2% |
| Azstarys | $13M | 6.5% |
| Symproic | $3.0M | 1.5% |
| Nucynta ERAG | $2.8M | 1.4% |
| Nucynta IRAG | $2.4M | 1.2% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $199.9M (+3.3%)
Jornay Pm grew +41% year on yearNucynta IR -46% year on year
Segment Latestquarter on quarteryear on year
- Belbuca$57.7M$57.7Mquarter on quarter +9.5%year on year +9.6%+9.5%+9.6%
- Jornay Pm$46.1M$46.1Mquarter on quarter +18%year on year +41%+18%+41%
- Xtampza ER$45.0M$45.0Mquarter on quarter -11%year on year -14%-11%-14%
- Nucynta ER$15.7M$15.7Mquarter on quarter -14%year on year -21%-14%-21%
- Nucynta IR$14.4M$14.4Mquarter on quarter -45%year on year -46%-45%-46%
- Azstarys$12.9M$12.9Mquarter on quarter n/ayear on year n/an/an/a
- Symproic$3.0M$3.0Mquarter on quarter -28%year on year -19%-28%-19%
- Nucynta ERAG$2.8M$2.8Mquarter on quarter +92%year on year n/a+92%n/a
- Nucynta IRAG$2.4M$2.4Mquarter on quarter +88%year on year n/a+88%n/a
Drug Manufacturers, Specialty & Generic
Ranks #7 of 41 by RyuScore